2012

Abiraterone Acetate (Zytiga) Approved to Treat Hormone-Refractory Prostate Cancer Before Chemotherapy.

In the past, when a prostate cancer patient became non-responsive (refractory) to hormonal therapy, the next step in his treatment was chemotherapy with taxotere (docetaxel). This treatment was usually accompanied by significant side effects.  Meanwhile, in April, 2011, the Food and Drug Administration (FDA) had initially approved abiraterone acetate (Zytiga) for use in patients whose prostate cancer had progressed more »

Recent Information on Prostate Cancer Screening and Active Surveillance.

The National Cancer Institute (NCI) is the largest of the numerous institutes comprising the National Institutes of Health (NIH) in Bethesda and Frederick, Maryland. The NCI publishes a monthly cancer bulletin focused on all types of cancer. The current special issue (NCI Cancer Bulletin, Vol. 9, November 27th, 2012) is specifically devoted to cancer screening. Screening is more »

An Example and a Purpose For Anyone with Prostate Cancer.

At some point in life, all of us will be diagnosed with a serious and perhaps life-threatening medical condition. How will we react in such a situation? Could such an unwanted circumstance have a deeper purpose? A difficult diagnosis and illness can be viewed as either a mirror or a window.  A dark adversity can represent a mirror in which we see ourselves and then are more »

Newly Diagnosed Prostate Cancer; What You Need to Know.

An extremely useful article was recently published by Nathan Roundy in the August, 2012 issue of the Prostate Cancer Research Institute (PCRI) Insights. The article is directed toward men who have been recently diagnosed with prostate cancer. It defines various medical terms and diagnostic and treatment details. Risk assessment tools are provided to help one determine more »

Identification of Localized Prostate Cancer Recurrence Using PET/CT Imaging.

It would be useful if one could detect and identify the location of localized prostate cancer recurrences and metastatic disease in early PSA recurrence in men who had previously failed initial cancer treatments. For example, such identified “focal” or local recurrences in 1-2 specific areas of the body could then be treated surgically or with targeted radiation. These areas of recurrence might not more »

Xtandi (Formerly MDV3100) Approved by the FDA for Treatment of Hormone- and Chemotherapy-Resistant Prostate Cancers.

On August 31st, 2012, the Food and Drug Administration (FDA) approved MDV3100 (now known as Xtandi) for treatment of prostate cancers in men who have previously failed hormone and chemo therapies. (See the full story in the August 31st issue of the Prostate Cancer Foundation, PCF, NewsPulse). In its Phase III clinical trials, Xtandi increased median more »

An Example of Potential New Prostate Cancer (PC) Treatments on the Horizon. Killing PC Cells With Radioactive Gold Nanoparticles Containing a Component of Tea as the Targeting Agent.

Nanotechnology is finding potential applications in many areas of our lives including cancer.  [A nanometer is defined as one billionth of a meter or one ten millionth of a centimeter (there are 2.54 centimeters per inch).] Synthetic nanometer-sized particles (such as atoms, molecules or fragments thereof usually less than 100 nanometers in size) are being used in many more »

Active Surveillance May Be the Preferred Option in Some Men with Prostate Cancer.

A recent study from Johns Hopkins University School of Medicine published in the Journal of Clinical Oncology concluded that for men over 65 “active surveillance is the first option for men in this category with very-low-risk disease” according to senior investigator Dr. H. Ballantine Carter. The initial question for such patients should be “whether any therapy is more »

PSA Screening Recommendations from the American Society of Clinical Oncology (ASCO).

The American Society of Clinical Oncology (ASCO) is a highly respected organization. On July 16th 2012, a committee of experts from ASCO published a provisional clinical opinion regarding PSA screening in the Journal of Clinical Oncology. This information is also summarized in the July 24th, 2012 issue of the National Cancer Institute (NCI) Bulletin. Briefly, ASCO experts concluded that for more »

Treating Low-Risk, Localized Prostate Cancer Using MRI-Guided Focal Laser Therapy.

The National Cancer Institute (NCI), the largest of the institutes comprising the National Insitutes of Health (NIH) in Bethesda and Frederick, Maryland is sponsoring a clinical trial for men who have slow-growing prostate cancer confined to a small portion of the prostate gland (low-volume disease). In this pilot study which is being conducted at the NIH more »

MDV3100 (enzalutamide) Now Available in Eleven (11) States.

The progress of developing new treatments for advanced prostate cancer continues. MDV3100 (now called enzalutamide) is being developed by Medivation Inc. and Astellas Pharma Inc. It is now available in eleven states as part of additional clinical trials in prostate cancer patients who have failed hormonal therapy and who have been previously treated with docetaxel (taxotere).  Enzalutamide more »

The U.S. Preventative Services Task Force Advises Against PSA Screening; a Summary of Responses.

    Since its October, 2011 initial advisory, and after receiving input from the medical community including many leading urologists and oncologists, the United States Preventative Services Task Force (USPSTF) recently issued its final recommendation against screening asymptomatic men for prostate cancer using the prostate-specific antigen (PSA) test.  (An earlier 2008 recommendation had advised against screening men over the age more »

New Developments in Prostate Cancer Biomarkers.

Two articles discussing the development of new genetic tests which could potentially be used to detect and determine aggressive prostate cancers were published in the May 2nd and May 15th  issues of the Zerohour Newsletter of the Project to End Prostate Cancer. The biggest problem facing men who have been diagnosed with prostate cancer is to determine whether the more »

A Vitamin D – Prostate Cancer Connection and Other News.

There has been much discussion concerning the role of blood vitamin D levels and its metabolism and their relationship to prostate cancer. A study examining this relationship published in the April 12th issue of the Journal of the National Cancer Institute found that men with the highest plasma levels of vitamin D “were 57% less likely to develop a lethal form of more »

HisProstateCancer.com, a Website for Wives and Family Members of Men With Prostate Cancer.

Recently I was contacted by a woman whose husband had been diagnosed with prostate cancer at the age of 49.  He underwent a radical prostatectomy and subsequent radiation therapy. Their experience led to the generation of the website, HisProstateCancer.com with its specific focus to wives, partners and family members of prostate cancer patients. I recommend this more »

A New Urine-Based PC Assay, Clinical Trials Providing Earlier Access to New Therapies and Other News from February-March, 2012.

It has been a month since I last updated this website and there have been significant news items which are summarized below. 1) FDA Approves a PCA3 Urine-Based Assay for Prostate Cancer that Could Reduce Unnecessary Prostate Biopsies.  On February 15th, 2012, the U.S. Food and Drug Administration (FDA) approved a urine-based molecular diagnostic test that more »

Positive Treatment Developments from Three Sources.

  At the Feb. 2nd-4th, 2012 meeting of the American Society of Clinical Oncology (ASCO), positive results were presented for two different prostate cancer treatments both currently under late stage Phase III clinical development. The positive results led to the studies being stopped earlier than anticipated.  These two drugs, radium-223 chloride (Alpharadin) and MDV3100 were more »